Molecular based strategies to generate protective immune responses to HIV-1

基于分子的策略产生针对 HIV-1 的保护性免疫反应

• 批准号: 7927825
• 负责人: YOSEF REFAELI
• 金额: $ 17.18万
• 依托单位: TAIGA BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7927825
• 关键词: Acquired Immunodeficiency Syndrome; Adjuvant; Adjuvant Study; Animals; Antibodies; Antibody Formation; Antibody Repertoire; Antibody Specificity; Antigenic Diversity; Antigens; Autoantibodies; Autoimmunity; B-Lymphocytes; Binding; Biological; Cancer Patient; Cardiolipins; Cells; Clinical Trials; Communicable Diseases; Development; Dose; Epitopes; Exposure to; Future; Gagging; Generations; Goals; HIV; HIV Antibodies; HIV Antigens; HIV Envelope Protein gp160; HIV Envelope Protein gp41; HIV Infections; HIV envelope protein; HIV-1; Hemagglutinin; Human; Immune response; Immune system; Immunity; Immunization; Individual; Inflammatory; Influenza; Infusion procedures; Lymphoid; Lymphoid Cell; Malaria; Molecular; Monoclonal Antibodies; Mus; Oils; Patients; Pattern; Phase; Preparation; Procedures; Production; Protein Isoforms; Proteins; Public Health; Relaxation; Self Tolerance; Serum; Signal Transduction; Specificity; T-Lymphocyte; Technology; Testing; Therapeutic; To autoantigen; Up-Regulation; Vaccination; Vaccine Adjuvant; Vaccine Antigen; Vaccine Design; Vaccines; Variant; Virus; anergy; autoreactive B cell; base; complementarity-determining region 3; design; efficacy testing; experience; gag Gene Products; gp160; human MPP1 protein; immunogenic; improved; in vivo; large scale production; neutralizing antibody; neutralizing monoclonal antibodies; novel; novel strategies; novel vaccines; peripheral tolerance; prophylactic; public health relevance; response; therapeutic vaccine

DESCRIPTION (provided by applicant): Using a new approach to adjuvant design we have identified a molecular based adjuvant that enhances immune response by several criteria including, an earlier response, a stronger response to more parts of the vaccine, and the ability to respond to very small amounts of vaccine. Phase I of this project involves applying the same technology to HIV-1 antigens. Phase II of the project will entail optimizing large-scale production of our adjuvant for studies in larger animals and eventual testing in human clinical trials. PUBLIC HEALTH RELEVANCE: This project seeks to further characterize a novel vaccine adjuvant that we have discovered that appears to enhance immune responses to difficult targets. Once this adjuvant has been validated against HIV-1 targets, the long-term goal for benefiting public health will be to use this adjuvant to improve vaccine strategies that target other infectious diseases such as Influenza and Malaria in addition to improving therapeutic vaccine approaches for cancer patients.

描述（由申请人提供）：使用佐剂设计的新方法，我们已经鉴定了一种基于分子的佐剂，其通过几个标准增强免疫应答，包括更早的应答、对疫苗更多部分的更强应答以及对非常少量的疫苗应答的能力。该项目的第一阶段涉及将同样的技术应用于HIV-1抗原。该项目的第二阶段将需要优化我们佐剂的大规模生产，用于大型动物的研究，并最终用于人体临床试验。 公共卫生关系：该项目旨在进一步表征我们发现的一种新型疫苗佐剂，该佐剂似乎可以增强对困难靶点的免疫反应。一旦这种佐剂针对HIV-1靶点得到验证，造福公共卫生的长期目标将是使用这种佐剂来改进针对流感和疟疾等其他传染病的疫苗策略，以及改进癌症患者的治疗性疫苗方法。